T/R potency <5% [Regulatives / Guidelines]

posted by dshah  – India, 2022-09-09 12:48 (1034 d 21:40 ago) – Posting: # 23282
Views: 4,608

Hi Achievwin!
Unlike Health Canada, there is no provision for potency correction in FDA.
So if the difference is more, there is higher probability to find difference in PK parameters for treatments, which ultimately affects BE outcome.
It's best to have less difference in Assay of Test and Reference for any BE study.
Regards,
Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,685 registered users;
53 visitors (0 registered, 53 guests [including 13 identified bots]).
Forum time: 10:29 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5